IP Library › Granted Patent US 11,154,484
Granted Patent B2
US 11,154,484 · App. 16/557,878 · Granted Oct 26, 2021

Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof

Inventors: Geoffrey C. Gurtner (Stanford, CA); Kenneth N. Horne (San Francisco, CA); Jayakumar Rajadas (Cupertino, CA)
Assignee: ALLERGAN HOLDINGS FRANCE S.A.S.
A61K8/735A61K8/027A61K8/0216A61K8/42A61K8/65A61K31/728A61L15/28A61L17/005A61L17/04A61L17/06A61L17/10A61L27/20A61L27/54A61L31/042A61Q19/08B29C48/05C08B37/0072C08L5/08A61K2800/805A61L2300/236A61L2300/402A61L2430/34C08L2205/025Y10T428/2929
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,484
App. No.
16/557,878
Granted
Oct 26, 2021
Kind
B2
Abstract

The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.

Claims (20)

1. An implantable device comprising:

a thread comprising uncrosslinked hyaluronic acid or salts, hydrates or solvates thereof and crosslinked hyaluronic acid or salts, hydrates or solvates thereof.

2. The device of claim 1 , wherein the crosslinked hyaluronic acid is crosslinked with a crosslinker selected from the group consisting of butanediol diglycidyl ether (BDDE), divinyl sulfone (DVS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC).

3. The device of claim 1 , wherein the crosslinked hyaluronic acid is crosslinked with butanediol diglycidyl ether (BDDE).

4. The device of claim 1 , wherein the thread further comprises a therapeutic agent.

5. The device of claim 4 , wherein the therapeutic agent is selected from the group consisting of lidocaine, xylocaine, novocaine, benzocaine, prilocaine, ropivacaine, propofol, and combinations thereof.

6. The device of claim 4 , wherein the therapeutic agent is lidocaine.

7. The device of claim 4 , wherein the therapeutic agent is selected from the group consisting of epinephrine, ephedrine, aminophylline, theophylline, and combinations thereof.

8. The device of claim 4 , wherein the therapeutic agent is botulism toxin.

9. The device of claim 4 , wherein the therapeutic agent is laminin-511, glucosamine, an antioxidant, insulin, a growth factor, an antibiotic agent, an anti-scarring agent, a peptide, an analgesic, or an antiseptic.

10. The device of claim 1 , wherein crosslinked hyaluronic acid has a degree of crosslinking with the crosslinker of between about 0.01% and about 20%.

11. The device of claim 1 , wherein crosslinked hyaluronic acid has a degree of crosslinking with the crosslinker of between about 0.1% and about 10%.

12. The device of claim 1 , wherein crosslinked hyaluronic acid has a degree of crosslinking with the crosslinker of between about 1% and about 8%.

13. The device of claim 1 , wherein the thread further comprises a diagnostic agent.

14. The device of claim 1 , wherein the thread has a tensile strength of between about 0 kpsi and about 250 kpsi.

15. The device of claim 1 , wherein the thread has an axial tensile strength of between about 0.01 lbs and about 10 lbs.

16. The device of claim 1 , wherein the thread has a diameter of between about 0.001 inches and about 0.100 inches.

17. The device of claim 1 , wherein the thread has an elasticity of between about 1% and about 200%.

18. The device of claim 1 , wherein the thread has a molecular weight of between about 0.1 MD and about 8 MD.

19. A product comprising the implantable device of claim 1 , wherein the product is configured for use as a dermal filler, wound dressing, or suture.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2021
From: TAUTONA GROUP, LP
To: ALINE AESTHETICS, LLC.
Reel/Frame 056492/0481 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2021
From: ALINE AESTHETICS, LLC.
To: ALLERGAN HOLDINGS FRANCE S.A.S.
Reel/Frame 056492/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: GURTNER, GEOFFREY C.; HORNE, KENNETH N.; RAJADAS, JAYAKUMAR
To: TAUTONA GROUP LP
Reel/Frame 056492/0420 →
Continuity (5)
Division 15864264 · Jan 8, 2018
Division 14947409 · Nov 20, 2015
Continuation 13060919
Provisional Application 61190866 · Sep 2, 2008
Related Publication 20200009038A1 · Jan 9, 2020